Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer

Area of Science:

• Urology
• Oncology
• Health Disparities

Background:

• Prostate cancer disproportionately affects Black men, with higher incidence, mortality, and advanced stage at diagnosis compared to White men.
• Prostate-specific antigen (PSA) is a critical serum marker for prostate cancer detection and management.
• Understanding racial differences in PSA levels is crucial for accurate diagnosis and treatment stratification.

Purpose of the Study:

• To investigate potential racial differences in pre-treatment prostate-specific antigen (PSA) levels among patients with local-regional prostate cancer.
• To determine if observed racial disparities in PSA levels persist after adjusting for clinical factors like tumor stage and grade.

Main Methods:

• Analysis of data from a cohort of 161 patients diagnosed with local-regional prostate cancer.
• Measurement of serum PSA levels using the immunoradiometric method.
• Statistical analysis including multivariate analysis to adjust for stage, grade, and socioeconomic factors (estimated median income).

Main Results:

• Mean PSA levels were significantly higher in Black patients compared to White patients (P = 0.022).
• This racial difference in PSA remained statistically significant in multivariate analysis after adjusting for stage and grade (P = 0.020).
• Racial differences in PSA were significant in one hospital but not another, indicating potential variability. Socioeconomic factors showed a correlation with PSA but did not fully explain the racial disparity.

Conclusions:

• The study suggests that racial differences in PSA levels, independent of tumor stage or grade, may exist in prostate cancer patients.
• Potential explanations include higher tumor cell burden or more aggressive biological behavior in Black patients.
• Further investigation is warranted to elucidate the underlying causes of these observed racial disparities in PSA levels.